Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma(Front. Oncol., (2022), 12, (1021632), 10.3389/fonc.2022.1021632)

dc.contributor.authorPrasopporn S.
dc.contributor.authorSuppramote O.
dc.contributor.authorPonvilawan B.
dc.contributor.authorJamyuang C.
dc.contributor.authorChanthercrob J.
dc.contributor.authorChaiboonchoe A.
dc.contributor.authorMore-Krong P.
dc.contributor.authorKongsri K.
dc.contributor.authorSuntiparpluacha M.
dc.contributor.authorChanwat R.
dc.contributor.authorKorphaisarn K.
dc.contributor.authorOkada S.
dc.contributor.authorSampattavanich S.
dc.contributor.authorJirawatnotai S.
dc.contributor.otherMahidol University
dc.date.accessioned2023-05-19T07:36:23Z
dc.date.available2023-05-19T07:36:23Z
dc.date.issued2023-01-06
dc.description.abstractIn the published article, there was an error in the Funding statement. There was one missing funding agency from our manuscript. The correct Funding statement appears below.Funding This study was funded by grants from the National Science and Technology Development Agency (NSTDA) of Thailand, the Japan Science and Technology Agency, and the National Institute of Allergy and Infectious Diseases of the United States as part of the e-ASIA Joint Research Program (e-ASIA JRP); the NSTDA (P-15- 50208), the National Research Council of Thailand (NRCT) R016441034, the Advanced Research in Pharmacology Fund, Siriraj Foundation (D003421), and by Mahidol University (Basic Research Fund, and the grant of fiscal year 2022). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
dc.identifier.citationFrontiers in Oncology Vol.12 (2023)
dc.identifier.doi10.3389/fonc.2022.1124912
dc.identifier.eissn2234943X
dc.identifier.scopus2-s2.0-85146757083
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/81688
dc.rights.holderSCOPUS
dc.subjectBiochemistry, Genetics and Molecular Biology
dc.titleCorrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma(Front. Oncol., (2022), 12, (1021632), 10.3389/fonc.2022.1021632)
dc.typeErratum
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85146757083&origin=inward
oaire.citation.titleFrontiers in Oncology
oaire.citation.volume12
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationNational Cancer Institute Thailand
oairecerif.author.affiliationChulabhorn Royal Academy
oairecerif.author.affiliationKumamoto University

Files

Collections